Join
Live feed
·
PRReleasevia Quantisnow
BioMarin Pharmaceutical Inc. logo

BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis

ByQuantisnow·Wall Street's wire, on your screen.
BMRN· BioMarin Pharmaceutical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMRN (BioMarin Pharmaceutical Inc.) and more on Quantisnow.